EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Journal Paper/Review - Jan 22, 2020
Smolen Josef S, Landewé Robert B M, Bijlsma Johannes W J, Burmester Gerd R, Dougados Maxime, Kerschbaumer Andreas, McInnes Iain B, Sepriano Alexandre, van Vollenhoven Ronald F, de Wit Maarten, Aletaha Daniel, Aringer Martin, Askling John, Balsa Alejandro, Boers Maarten, den Broeder Alfons A, Buch Maya H, Buttgereit Frank, Caporali Roberto, Cardiel Mario Humberto, De Cock Diederik, Codreanu Catalin, Cutolo Maurizio, Edwards Christopher John, van Eijk-Hustings Yvonne, Emery Paul, Finckh Axel, Gossec Laure, Gottenberg Jacques-Eric, Hetland Merete Lund, Huizinga Tom W J, Koloumas Marios, Li Zhanguo, Mariette Xavier, Müller-Ladner Ulf, Mysler Eduardo F, da Silva Jose A P, Poór Gyula, Pope Janet E, Rubbert-Roth Andrea, Ruyssen-Witrand Adeline, Saag Kenneth G, Strangfeld Anja, Takeuchi Tsutomu, Voshaar Marieke, Westhovens René, van der Heijde Désirée
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field.
An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019. A predefined voting process was applied, current levels of evidence and strengths of recommendation were assigned and participants ultimately voted independently on their level of agreement with each of the items.
The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering on sustained clinical remission is provided. Cost and sequencing of b/tsDMARDs are addressed. Initially, MTX plus GCs and upon insufficient response to this therapy within 3 to 6 months, stratification according to risk factors is recommended. With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAK inhibitor should be added to the csDMARD. If this fails, any other bDMARD (from another or the same class) or tsDMARD is recommended. On sustained remission, DMARDs may be tapered, but not be stopped. Levels of evidence and levels of agreement were mostly high.
These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.